184 related articles for article (PubMed ID: 10640303)
1. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
Pauwels PJ; Tardif S; Wurch T; Colpaert FC
J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
[TBL] [Abstract][Full Text] [Related]
2. Enhanced stability of wild-type and constitutively active alpha(2A)-adrenoceptors by ligands with agonist, silent and inverse agonist properties.
Pauwels PJ; Tardif S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):134-41. PubMed ID: 12122500
[TBL] [Abstract][Full Text] [Related]
3. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
Pauwels PJ; Gouble A; Wurch T
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
[TBL] [Abstract][Full Text] [Related]
4. Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
Pauwels PJ; Tardif S; Colpaert FC; Wurch T
Biochem Pharmacol; 2001 May; 61(9):1079-92. PubMed ID: 11301041
[TBL] [Abstract][Full Text] [Related]
5. Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions.
Pauwels PJ; Colpaert FC
Br J Pharmacol; 2000 Dec; 131(7):1385-90. PubMed ID: 11090111
[TBL] [Abstract][Full Text] [Related]
6. Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.
Pauwels PJ; Colpaert FC
Br J Pharmacol; 2000 Aug; 130(7):1505-12. PubMed ID: 10928951
[TBL] [Abstract][Full Text] [Related]
7. Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated alpha 2A-adrenoceptor states: evidence for effector pathway-dependent differential antagonism.
Pauwels PJ; Rauly I; Wurch T
J Pharmacol Exp Ther; 2003 Jun; 305(3):1015-23. PubMed ID: 12649300
[TBL] [Abstract][Full Text] [Related]
8. Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.
Pauwels PJ; Wurch T; Tardif S; Finana F; Colpaert FC
Naunyn Schmiedebergs Arch Pharmacol; 2001 May; 363(5):526-36. PubMed ID: 11383713
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal modulation of alpha(2A)-adrenoceptor and G(alpha o) protein states as determined by carboxy-terminal mutagenesis of a G(alpha o) protein.
Wurch T; Okuda J; Pauwels PJ
Mol Pharmacol; 2001 Oct; 60(4):666-73. PubMed ID: 11562427
[TBL] [Abstract][Full Text] [Related]
10. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
Millan MJ; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet JM; Brocco M; Duqueyroix D; Nicolas JP; Boutin JA; Newman-Tancredi A
J Pharmacol Exp Ther; 2001 Jun; 297(3):876-87. PubMed ID: 11356907
[TBL] [Abstract][Full Text] [Related]
11. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.
Wurch T; Boutet-Robinet EA; Palmier C; Colpaert FC; Pauwels PJ
J Pharmacol Exp Ther; 2003 Jan; 304(1):380-90. PubMed ID: 12490615
[TBL] [Abstract][Full Text] [Related]
12. Ligand-receptor interactions as controlled by wild-type and mutant Thr(370)Lys alpha2B-adrenoceptor-Galpha15 fusion proteins.
Pauwels PJ; Tardif S; Finana F; Wurch T; Colpaert FC
J Neurochem; 2000 Jan; 74(1):375-84. PubMed ID: 10617142
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous ligand-mediated Ca(++) responses at wt and mutant alpha(2A)-adrenoceptors suggest multiple ligand activation binding sites at the alpha(2A)-adrenoceptor.
Pauwels PJ; Colpaert FC
Neuropharmacology; 2000 Aug; 39(11):2101-11. PubMed ID: 10963753
[TBL] [Abstract][Full Text] [Related]
14. Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits.
Pauwels PJ; Rauly I; Wurch T; Colpaert FC
Neuropharmacology; 2002 May; 42(6):855-63. PubMed ID: 12015212
[TBL] [Abstract][Full Text] [Related]
15. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
[TBL] [Abstract][Full Text] [Related]
16. Bidirectional allosteric effects of agonists and GTP at alpha(2A/D)-adrenoceptors.
Tian WN; Miller DD; Deth RC
J Pharmacol Exp Ther; 2000 Feb; 292(2):664-71. PubMed ID: 10640304
[TBL] [Abstract][Full Text] [Related]
17. Measurement of agonist-dependent and -independent signal initiation of alpha(1b)-adrenoceptor mutants by direct analysis of guanine nucleotide exchange on the G protein galpha(11).
Carrillo JJ; Stevens PA; Milligan G
J Pharmacol Exp Ther; 2002 Sep; 302(3):1080-8. PubMed ID: 12183666
[TBL] [Abstract][Full Text] [Related]
18. G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors.
Wurch T; Colpaert FC; Pauwels PJ
Br J Pharmacol; 1999 Feb; 126(4):939-48. PubMed ID: 10193774
[TBL] [Abstract][Full Text] [Related]
19. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors.
González-Maeso J; Rodríguez-Puertas R; Meana JJ; García-Sevilla JA; Guimón J
Mol Psychiatry; 2002; 7(7):755-67. PubMed ID: 12192620
[TBL] [Abstract][Full Text] [Related]
20. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
Newman-Tancredi A; Nicolas JP; Audinot V; Gavaudan S; Verrièle L; Touzard M; Chaput C; Richard N; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):197-206. PubMed ID: 9750005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
